← Eichor
Condition: Genetic Mutations Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Genetic Mutations

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Can
Phase 3 · 49 location(s) · Dizal (Jiangsu) Pharmaceutical Co., Ltd. · NCT07182682Li-Fraumeni Syndrome/TP53 Biobank
Phase N/A · 2 location(s) · Abramson Cancer Center at Penn Medicine · NCT04367246Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer
Phase N/A · 71 location(s) · Royal Marsden NHS Foundation Trust · NCT04050345Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100Research of Therapeutic Targets in the Frame of Nephronophthisis and Renal Associated Ciliopathies
NA · 1 location(s) · Imagine Institute · NCT06648044TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Phase 2 · 1 location(s) · TYK Medicines, Inc · NCT05948813Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Phase 2 · 18 location(s) · VA Office of Research and Development · NCT04038502IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations
Phase 1 · 1 location(s) · Shanghai Pudong Hospital · NCT06487377Molecular Biology of Polycythemia and Thrombocytosis
Phase N/A · 1 location(s) · University of Utah · NCT00722527Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Phase 1/Phase 2 · 5 location(s) · Anbogen Therapeutics, Inc. · NCT05532696MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Phase 1/Phase 2 · 25 location(s) · Merck Sharp & Dohme LLC · NCT07286149Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
Phase 1 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07134998Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated A
Phase 1 · 7 location(s) · Tenaya Therapeutics · NCT06228924GENetic Fronto Temporal Dementia Initiative in Lille
NA · 1 location(s) · University Hospital, Lille · NCT04639622A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Phase 1 · 6 location(s) · Cogent Biosciences, Inc. · NCT07361562A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
Phase 1 · 1 location(s) · National Cancer Center, China · NCT06362980Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT00006150Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Wi
Phase 3 · 274 location(s) · SWOG Cancer Research Network · NCT06998940Circulating Tumor DNA After Neoadjuvant Chemotherapy
NA · 1 location(s) · Institut Bergonié · NCT03357120A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Phase 3 · 132 location(s) · National Cancer Institute (NCI) · NCT04166409Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT07019155A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
NA · 45 location(s) · UNICANCER · NCT05639413Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07500441Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations
Phase N/A · 1 location(s) · Institute of Cancer Research, United Kingdom · NCT02705846Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT06440954T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid
Phase 1 · 2 location(s) · Tao Zhang · NCT06484556World Data on Ambroxol for Patients With GD and GBA Related PD
Phase N/A · 3 location(s) · Shaare Zedek Medical Center · NCT04388969Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis
Phase 2 · 3 location(s) · SpliSense Ltd. · NCT06429176A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05010031
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.